Given the prevalence of behavioral health issues that often accompany chronic diseases, pairing a pharmacotherapy with a digital therapeutic aimed at driving behavioral change would at first blush seem a natural fit. For example, many psychiatric conditions including depression, anxiety and sleep disorders occur during or as a consequence of treatment of all sorts of diseases. In 2021, psychiatry-related prescription digital therapeutics accounted for 37% of digital therapeutics across all phases of development as well as the majority of digital care programs, according to data from IQVIA.
More generally, behavioral change, including treatment with conventional cognitive behavioral therapy (CBT), can improve outcomes in many major diseases and...